Docosanol

Docosanol (1-Docosanol / Behenyl Alcohol): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Synonyms

1-Docosanol, also known as behenyl alcohol, is a saturated fatty alcohol containing 22 carbon atoms. It is listed under several synonyms and identifiers, including behenic alcohol, behenyl alcohol, docosan-1-ol, n-docosanol, docosyl alcohol, the brand names Abreva and Lidakol, and the CAS registry number 661-19-8. Its ATC class is D06BB11 and its molecular formula is C₂₂H₄₆O.

Chemical Structure and Properties

1-Docosanol is a saturated aliphatic alcohol with a 22-carbon chain, known as docosane, with a hydroxy group (–OH) at the terminal carbon and the formula CH₃(CH₂)₂₁OH. It has a molecular weight of 326.60. Pharmacological formulations of 1-docosanol are complex due to its near-zero aqueous solubility. When formulated as the approved pharmaceutical product, it is supplied as a smooth, odorless, tasteless white cream that dries clear.

Natural Occurrence and Sources

1-Docosanol is a long-chain fatty alcohol derived from natural sources, such as vegetable oils. Behenic alcohol or behenyl alcohol (n-docosanol) is identified in wood extracts of Populus tremuloides (trembling aspen). Policosanols are the chemical name for a mixture of long-chained aliphatic primary alcohols, containing mostly docosanol (C22:0), hexacosanol (C26:0), octacosanol (C28:0), triacontanol (C30:0), and dotriacontanol (C32:0). They are commercially obtained from sugarcane and cereal germs from the milling industries. Policosanol represents a mixture of long-chain fatty alcohols (20–36 carbon) mostly comprised of docosanol (C22), tetracosanol (C24), hexacosanol (C26), octacosanol (C28), and triacontanol (C30). Rice bran is a good source of policosanol-containing waxes, including docosanol (C22).

Common Forms and Preparations

Docosanol is used traditionally as an emollient, emulsifier, and thickener in cosmetics, as a nutritional supplement (as an individual entity and also as a constituent of policosanol), and as an FDA-approved pharmaceutical (Abreva), approved as an antiviral agent for reducing the duration of cold sores caused by the herpes simplex virus. The pharmaceutical is marketed in the US as a 10% topical cream. It is available as a 10% cream in 2-gram tubes as an OTC product.

2. Traditional and Historical Use

The industrial and cosmetic history of docosanol predates its pharmaceutical development. Traditionally, n-docosanol has been used as a thickening agent, emollient, and emulsifier in cosmetics formulations. It has been widely used as a raw material in the synthesis of various compounds, including surfactants, lubricants, and emulsifiers. In the field of materials science, 1-docosanol has been utilized as a surface modifier or coating agent.

In the cosmetics industry specifically, behenyl alcohol (docosanol) is primarily used as an emulsifier, emollient, thickener, and opacifying ingredient, and is found mainly in face moisturizers and body lotions, but can also be used in deodorant, lipstick, foundation, and hair care products. It is commercially used in moisturizers and hair-conditioning formulations. These cosmetic uses did not derive from any specific ethnomedical tradition; rather, they emerged from the industrial-era identification of long-chain fatty alcohols as effective skin-conditioning and formulation agents.

There is no documented record of docosanol as such being used in any traditional herbal medicine system (e.g., Ayurveda, Traditional Chinese Medicine, or Indigenous herbalism) in the form of an isolated compound. However, plant waxes and vegetable oils rich in fatty alcohols such as docosanol—including sugarcane wax, cereal bran waxes, and certain tree barks—have long histories of use in various cultures as topical skin-conditioning agents, though these preparations were not standardized for docosanol content.

The antiviral application of docosanol is entirely a product of late-twentieth-century pharmaceutical science. N-docosanol was approved by the US Food and Drug Administration (FDA) as a pharmaceutical antiviral agent to treat cold sores following several decades of laboratory and clinical investigation beginning in the early 1990s.

3. Key Constituents and Active Compounds

Unlike multi-component herbal preparations, docosanol as a pharmaceutical and supplement entity is itself the active compound. Docosanol (n-docosanol; behenyl alcohol) is a 22-carbon, saturated, primary alcohol that inhibits a broad spectrum of lipid-enveloped viruses (e.g., HSV, RSV, HCMV, and VZV) based on in vitro experiments. When present as a component of the policosanol mixture, it occurs alongside other long-chain fatty alcohols, but its pharmaceutical applications exploit the pure compound.

The metabolic fate of topically applied docosanol has not been fully determined. It is metabolized to n-docosanoic acid and incorporated into cellular lipids and phospholipids. This is evidenced by incorporation of up to 60% of cell-associated radiolabel into phospholipids that co-purify with phosphatidylcholine and phosphatidylethanolamine. Analysis by chemical reduction suggests that a significant portion of n-docosanol is oxidized to n-docosanoic acid and then incorporated as an acyl group on polar lipids. This metabolic conversion appears to be integral to its antiviral activity rather than being incidental.

4. Mechanisms of Action

Antiviral Mechanism: Viral Fusion Inhibition

The 22-carbon fatty alcohol, n-docosanol, exhibits in vitro antiviral activity against several lipid-enveloped viruses including herpes simplex viruses 1 and 2 by a mechanism that interferes with normal viral entry into target cells. Critically, docosanol is not directly virucidal, and its principal anti-HSV mechanism of action in vitro apparently relates to interference with viral fusion to host cell membranes early in replication, although other inhibitory effects may be possible.

Early mechanistic work published in PNAS (1991) established the foundational evidence: susceptible viruses included wild-type herpes simplex viruses 1 and 2 as well as acyclovir-resistant herpes simplex virus 2 and also respiratory syncytial virus—all of which are lipid-enveloped. In contrast, nonenveloped poliovirus was not susceptible to the inhibitory action of 1-docosanol. This selectivity strongly implicated the lipid envelope as the target.

Subsequent research refined the mechanism: previous studies of the mechanism of action demonstrated that n-docosanol inhibits an event prior to the expression of intermediate early gene products but subsequent to HSV attachment. The studies reported indicate that n-docosanol inhibits fusion of the HSV envelope with the plasma membrane. Reduced expression of viral genes in n-docosanol-treated cells was confirmed by a 70% reduction in expression of a reporter gene regulated by a constitutive promoter inserted into the viral genome. Inhibited release in treated cells of virion-associated regulatory proteins—an immediate post-entry event—was indicated by a 75% reduction in the expression of beta-galactosidase in target cells carrying a stably transfected lacZ gene under control of an HSV immediate-early promoter. Finally, the fusion-dependent dequenching of a lipophilic fluorescent probe (octadecyl rhodamine B chloride) inserted into the HSV envelope was significantly inhibited in treated cells. Inhibition of fusion between the plasma membrane and the HSV envelope, and the subsequent lack of replicative events, may be the predominant mechanism for the anti-HSV activity of n-docosanol.

Detailed HSV studies reveal that following cellular metabolism, docosanol interferes with one or more steps of viral entry, although docosanol does not affect binding of HSV to target cells. HSV virions bound to target cell receptors remain on the cell surface for a prolonged time. Studies using fluorescently labeled HSV confirm that fusion of the viral envelope with the cell membrane is inhibited.

Although its mechanism of drug action is still debated, docosanol is believed to prevent virus entry by interfering with the interaction between epithelial cell membrane receptors and HSV envelope proteins. True antivirals inhibit viral DNA replication, which may result in mutations of HSV rendering them resistant. Since docosanol does not affect the synthesis and replication of the virus, but modulates the host cell to prevent entry of the virion, development of resistance to docosanol is unlikely.

Furthermore, conditions that increase the amount of n-docosanol metabolism increase the amount of antiviral activity, suggesting that this intracellular metabolic conversion of the drug is required for antiviral activity. Cellular resistance to infection declines after removal of the drug with a t_1/2 of approximately 3 hours.

A non-antiviral mechanism of action resulting from anti-inflammatory effects has also been described, though the clinical significance of this secondary mechanism has not been extensively characterized in published human studies.

Spectrum of Activity

Docosanol exhibits antiviral activity in vitro against many lipid-enveloped viruses, including HSV-1, HSV-2, VZV (varicella-zoster virus), CMV (cytomegalovirus), HHV-6 (human herpesvirus-6), RSV (respiratory syncytial virus), influenza A, and HIV-1. Preliminary in vitro data suggest that docosanol also inhibits replication of HIV-1 and other retroviruses such as HTLV-1 and -2. However, while some in vivo data show docosanol's activity against CMV and RSV, clinical studies have yet to be conducted demonstrating its usefulness for these other viruses (i.e., RSV, CMV, HIV-1, etc.).

5. Scientific Evidence by Area of Use

5.1 Recurrent Herpes Labialis (Cold Sores / Fever Blisters) — Primary Approved Indication

Regulatory Status

In July 2000, docosanol was approved for medical use in the United States as an antiviral agent for reducing the duration of cold sores. It is an over-the-counter medication (OTC) sold under the brand name Abreva, among others. Approved by the FDA in July 2000, docosanol remains the only over-the-counter medication in clinical use for cold sores and fever blisters. Docosanol is the first topical antiviral approved for over-the-counter use in recurrent herpes labialis.

Disease Background

Recurrent herpes labialis is a painful and potentially disfiguring infection affecting an estimated 40 million people in the US alone. The majority of recurrences are caused by herpes simplex virus type 1. Recurrent herpes simplex labialis (HSL) occurs in 20% to 40% of the US population. Although the disease is self-limiting in persons with a healthy immune response, patients seek treatment because of the discomfort and visibility of a recurrent lesion.

Pivotal Clinical Trial (Sacks et al., 2001)

The primary regulatory evidence for docosanol came from two identically designed, multicenter clinical trials reported together. The purpose was to determine whether docosanol 10% cream is efficacious compared with placebo for the topical treatment of episodes of acute HSL; two identical double-blind, placebo-controlled studies were conducted at a total of 21 sites. Otherwise healthy adults with documented histories of HSL were randomized to receive either docosanol or polyethylene glycol placebo and initiated therapy in the prodrome or erythema stage of an episode. Treatment was administered 5 times daily until healing occurred (i.e., the crust fell off spontaneously or there was no longer evidence of an active lesion), with twice-daily visits.

The median time to healing in the 370 docosanol-treated patients was 4.1 days, 18 hours shorter than observed in the 367 placebo-treated patients (P = .008; 95% CI: 2, 22). The docosanol group also exhibited reduced times from treatment initiation to: (1) cessation of pain and all other symptoms (itching, burning, and/or tingling; P = .002; 95% CI: 3, 16.5); (2) complete healing of classic lesions (P = .023; 95% CI: 1, 24.5); and (3) cessation of the ulcer or soft crust stage of classic lesions (P < .001; 95% CI: 8, 25).

Additional Randomized Controlled Trial (Habbema et al., 1996)

A separate earlier randomized, double-blind, parallel group, placebo-controlled study was conducted in 63 patients: n-Docosanol has been shown to have antiviral activity. To demonstrate the efficacy of n-docosanol 10% cream in the treatment of recurrent herpes labialis, a randomised, double-blind, parallel group, placebo-controlled study was undertaken in 63 patients. In a crossover extension, 22 of the patients used the alternative treatment for a further episode; a total of 98 episodes were evaluated. Application of n-docosanol 10% cream early in the prodromal or erythema stage of a recurrent episode of herpes labialis shortened mean healing time by approximately 3 days, as compared to late treatment with n-docosanol 10% cream and early or late treatment with the placebo. The crossover study revealed that late treatment with n-docosanol 10% cream significantly reduced mean healing time compared to placebo. Treatments were well tolerated.

Docosanol vs. Acyclovir: Head-to-Head Evidence

A trial in 474 patients showed no tangible difference between docosanol and 5% aciclovir in reducing healing time. This finding positions docosanol as broadly comparable in efficacy to topical acyclovir for this indication.

Systematic Reviews and Meta-Analyses

Multiple systematic reviews have assessed the totality of evidence. A 2018 systematic review from the European Medical Journal encompassing 20 papers (19 randomized controlled trials and one quasi-randomized trial) found that the efficacy of topical acyclovir, penciclovir, and docosanol compared to placebo is marginal at best (shortening the duration of pain by less than 24 hours), although the three topical antiherpetic drugs have no serious adverse reactions and are safe to use. In the 20 studies reviewed, all three topical agents were well tolerated. Most subjects had no reaction or minimal localized reactions that occurred at rates similar to placebo. Localized reactions included inflammation and dry skin. There were no systematic adverse events reported in any of the studies.

A 2023 network meta-analysis in the Journal of Evidence Based Dental Practice, searching Ovid Medline, PubMed, CENTRAL, Scopus, and ClinicalTrials.gov, examined the comparative efficacy and safety of antiviral agents for prevention and management of herpes labialis across RCTs. The review found that valacyclovir plus a steroid produced the best results in the network, placing the benefit of topical agents including docosanol in a relative context against more potent systemic regimens.

The Johns Hopkins ABX Guide summarizes the clinical balance concisely: docosanol is best suited for immunocompetent patients with mild recurrent herpes labialis who want an OTC option and can start treatment at the prodrome; it is not a substitute for systemic therapy when episodes are severe, frequent, or atypical. It is used against labial herpes, not genital outbreaks. Clinical benefit is modest, with approximately 18 hours of reduced healing time in the pivotal RCT. The inconvenience of 5× per day administration, cost, and minimal benefit probably should limit the use of this OTC product.

Activity Against Acyclovir-Resistant HSV

Docosanol has in vitro activity against acyclovir-resistant HSV. Because its mechanism differs from that of nucleoside analogues such as acyclovir, in vitro activity extends to acyclovir-resistant HSV isolates; however, clinical outcome data specifically supporting its use for acyclovir-resistant herpes labialis are limited. Docosanol has been shown to be effective in acyclovir-resistant HSV strains in vitro, though translation of this to clinical practice remains to be confirmed in controlled trials.

Evidence Strength Summary for Herpes Labialis: The evidence is moderate in strength. The indication is supported by two identical pivotal RCTs (combined n = ~737 patients) and is FDA-approved. The clinical benefit—approximately 18 hours' reduction in healing time—is statistically significant but modest. Systematic reviews confirm safety across all trials but characterize the magnitude of benefit as marginal. Early initiation of treatment (prodromal/erythema stage) is consistently associated with greater benefit.

5.2 Kaposi's Sarcoma in HIV-Infected Patients — Exploratory/Pilot

Docosanol inhibits a broad spectrum of lipid-enveloped viruses in vitro including HSV-1, HSV-2, VZV, CMV, HHV-6, and HIV-1. These observations led researchers to conduct a pilot clinical study with docosanol 10% cream as a topical treatment for Kaposi's sarcoma (KS) in HIV-1-infected patients. In this open-label study, 28 cutaneous KS lesions in 10 HIV-1-infected patients were treated topically five times daily for 4 weeks with evaluation of lesion characteristics of area, edema, and color. All patients elected to enroll in an extended treatment protocol and continued to treat for up to 35 weeks. Within 28 days, 2 of 10 patients exhibited a partial response based on standardized criteria exhibiting 74 to 83% reductions in total target lesion areas. The researchers noted that the study's ability to determine efficacy was limited because it was an open-label study without a placebo group, and because patients did not discontinue their established antiviral regimens. In addition, ACTG response criteria were not employed. The study nevertheless showed that docosanol can be used safely in immunocompromised individuals and that it may exert clinical benefits on cutaneous KS lesions in HIV-positive patients, indicating that docosanol 10% cream merits further investigation as a topical therapy for the treatment of cutaneous KS disease.

Evidence Strength for KS: Very preliminary. Single open-label pilot study, no placebo control, small sample (n = 10). No definitive conclusion can be drawn; further controlled investigation has not been published as of the available literature.

5.3 Other Lipid-Enveloped Viruses — In Vitro Only

Docosanol is active in vitro against herpes viruses types 1 and 2, cytomegalovirus, influenza virus, human herpesvirus-6, and respiratory syncytial virus, all of which are enveloped viruses. Some in vivo data show docosanol's activity against CMV and RSV. However, clinical studies have yet to be conducted demonstrating its usefulness for these other viruses.

Evidence Strength for Other Viruses: Entirely preclinical (in vitro and limited animal data). No human clinical trials have been conducted for these additional viral targets.

5.4 Topical Cosmetic / Emollient Use

Docosanol's use as an emollient and skin-conditioning agent in cosmetics is well established industrially but has not been subjected to formal randomized clinical trials specifically evaluating its emollient properties. Its function in this context derives from its physicochemical properties as a long-chain fatty alcohol. It is also commercially used in moisturizers and hair-conditioning formulations.

6. Body Systems and Health Areas Associated with Docosanol

• Integumentary system (skin and mucous membranes): The approved pharmaceutical indication is treatment of cold sores/fever blisters on the face or lips, with shortening of healing time and duration of symptoms including tingling, pain, burning, and/or itching.
• Immune/antiviral defense: In the drug group of entry inhibitors, docosanol is classified alongside enfuvirtide (HIV), palivizumab (RSV), and VZV antibody drugs, representing a distinct antiviral pharmacological class targeting viral entry rather than replication.
• Lipid/cellular membrane biology: Docosanol's metabolic conversion into phospholipids and its integration into cell membranes link it mechanistically to membrane-structural biology.
• Oncology (exploratory): Pilot evidence, described above, associates docosanol topical therapy with cutaneous Kaposi's sarcoma lesions in HIV-infected patients, though this remains unvalidated in controlled trials.

7. Dosage Forms and Dosages Reported in Studies

Approved Pharmaceutical Dosage Form

Docosanol is classified as a saturated aliphatic alcohol with antiviral activity against Herpesviridae, indicated for topical treatment of recurrent herpes labialis (perioral herpes, cold sores, fever blisters). It is applied topically to affected areas of the lips and surrounding skin as a 10% cream; it should not be applied in or near the eyes or inside the mouth.

Dosing Regimen from Clinical Trials

In the pivotal multicenter RCT, otherwise healthy adults were randomized to receive either docosanol or polyethylene glycol placebo and initiated therapy in the prodrome or erythema stage of an episode. Treatment was administered 5 times daily until healing occurred. Patients used the cream at the first sign or symptom of a herpes recurrence and subsequently applied the cream five times a day until the lesions healed, up to a maximum of 10 days.

For adults and children aged 12 years and older: apply a small amount 5 times daily to sores on lips or face until healed. For patients aged ≥12 years, the regimen is 5 applications per day topically; for children under 12 years, safety and efficacy have not been established.

Kaposi's Sarcoma Pilot Study Dosing

In the open-label KS study, 28 cutaneous KS lesions in 10 HIV-1-infected patients were treated topically five times daily for 4 weeks, with some patients continuing for up to 35 weeks.

Animal Studies Dosing (Reproductive Toxicology)

No evidence of impaired fertility or harm to the fetus due to docosanol administered in oral doses of 10, 500, 1000, or 2000 mg/kg/day was observed in reproduction studies performed in rats and rabbits. Based on the lack of absorption of topically applied docosanol, these tested doses are a thousand-fold higher than the human dose.

8. Pharmacokinetics

Docosanol is not appreciably absorbed into the systemic circulation following topical application to healthy skin or herpes labialis lesions. In vitro studies using cadaver skin indicate that dermal penetration following topical application is minimal and appears to be limited to the dermis and stratum corneum.

The official Canadian product monograph provides a pharmacokinetic analysis from a human study: ten women with active oral-facial herpes simplex lesions were treated with Abreva, applied as a single dose (Day 1), and as multiple topical doses (five times daily, Days 2 and 3). Blood samples were withdrawn at intervals up to 24 hours after treatment and analyzed for docosanol. Of the 209 plasma samples analyzed, the docosanol level was below the limit of quantitation in 208. This pharmacokinetic data confirms that systemic exposure after topical application is negligible.

Based on 1-docosanol's estimated log K_ow, it will likely be distributed to fatty tissues in the body if absorbed; however, it is expected to be excreted through urine and feces. All QSAR simulators tested reported docosanoic acid as a putative metabolite.

9. Safety Considerations

General Tolerability

Despite its potential to be a mild irritant, this antiviral was well-tolerated in clinical trials. In the 20 studies reviewed in a systematic review of topical antiherpetics, all three topical agents (acyclovir, penciclovir, and docosanol) were well tolerated. Most subjects had no reaction or minimal localized reactions occurring at rates similar to placebo. Localized reactions included inflammation and dry skin. There were no systematic adverse events reported in any of the studies.

Adverse Effects

One of the most common side effects reported from docosanol is headache. Headaches caused by the medication tend to be mild and can occur in any region of the head. In clinical trials, headache occurred in 10.4% of people treated with docosanol cream and 10.7% of people treated with placebo. The near-identical rate between active and placebo groups indicates this is not a drug-specific effect.

Other reported adverse events include headache and application site reactions such as burning and stinging, as well as herpes simplex lesions outside of the treatment area. Additional reported side effects include acne, burning, dryness, itching, rash, redness, acute diarrhea, soreness, and swelling.

The most serious side effects, although rare, are allergic reactions. Some patients have experienced symptoms of allergic reactions including difficulty breathing, confusion, angioedema (facial swelling), fainting, dizziness, hives, or chest pain.

Contraindications

Docosanol is contraindicated in individuals with hypersensitivity to docosanol or any other components of the formulation (which include benzyl alcohol, mineral oil, propylene glycol, or sucrose in the branded product).

Drug Interactions

There are no known interactions between docosanol and other medicines. There are no drug interactions associated with docosanol products. This absence of clinically recognized drug–drug interactions is consistent with the negligible systemic absorption of the topically applied compound.

Use in Specific Populations

Pregnancy: No evidence of impaired fertility or harm to the fetus was observed in reproduction studies in rats and rabbits at oral doses up to 2000 mg/kg/day, which are a thousand-fold higher than the human dose. However, no adequate and well-controlled studies have been conducted in pregnant humans. A review of topical antiviral use in pregnancy concluded that docosanol is likely safe but should be utilized as a second-line agent in pregnancy.

Lactation: It is not known whether docosanol is excreted in human milk. The clinical relevance of this uncertainty is moderated by the demonstrated negligible systemic absorption.

Pediatrics: Safety and effectiveness in pediatric patients have not been established. Abreva has not been studied in children under 12 years of age.

Immunocompromised patients: Safety and efficacy in immunocompromised individuals have not been established. The treatment is best suited for immunocompetent patients with mild recurrent herpes labialis; it is not a substitute for systemic therapy when episodes are severe, frequent, or atypical.

Resistance Potential

Anti-viral long-chain aliphatic compounds are considered to have a special mechanism of action and are not expected to lead to viral resistance to the treatment. This theoretical advantage over nucleoside analogues arises because docosanol targets the host cell membrane rather than a viral enzyme susceptible to mutation-driven resistance.

Environmental Toxicology

The weight of the scientific evidence provides sufficient information to indicate that 1-docosanol has low potential for bioaccumulation in the environment based on low-concern assessments.

References

• Katz DH et al. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proc Natl Acad Sci USA, 1991; 88:10825–10829. PMC53024.
• Marcelletti JF et al. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res, 1999;40(3):175–85. PMID: 9864049.
• Sacks SL et al. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol. 2001;45(2):222–30.
• Habbema L et al. n-Docosanol 10% cream in the treatment of recurrent herpes labialis: a randomised, double-blind, placebo-controlled study. Acta Derm Venereol. 1996.
• Treister NS, Woo SB. Topical n-docosanol for management of recurrent herpes labialis. Expert Opin Pharmacother. 2010;11(5):853–60. PMID: 20210688.
• Docosanol: new drug. Herpes labialis: barely more effective than an excipient. Prescrire Int. 2009;18(101):106–7. PMID: 19637417.
• Scolaro MJ et al. The antiviral drug docosanol as a treatment for Kaposi's sarcoma lesions in HIV type 1-infected patients: a pilot clinical study. AIDS Res Hum Retroviruses. 2001. PMID: 11177381.
• De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29(3):695–747. PMC4978613.
• Hammer KDP et al. A Systematic Review on the Efficacy of Topical Acyclovir, Penciclovir, and Docosanol for the Treatment of Herpes Simplex Labialis. Eur Med J Dermatol. 2018.
• Koe KH et al. Comparative Efficacy of Antiviral Agents for Prevention and Management of Herpes Labialis: A Systematic Review and Network Meta-Analysis. J Evid Based Dent Pract. 2023;23(1):101778.
• Mancini A et al. Topical and Systemic Therapeutic Approaches in the Treatment of Oral Herpes Simplex Virus Infection: A Systematic Review. Int J Mol Sci. 2025;26(17):8490.
• DailyMed. Docosanol Cream — Drug Label (NIH/NLM).
• Health Canada. Product Monograph: ABREVA® Docosanol Cream, 10%. Health Canada Drug Product Database.
• FDA. Docosanol Topical Cream Product-Specific Guidance. U.S. Food and Drug Administration.
• Drugs.com. Docosanol Monograph for Professionals (AHFS/PDR).
• Johns Hopkins ABX Guide. Docosanol.
• ScienceDirect Topics. Docosanol — overview (Biochemistry, Genetics and Molecular Biology).
• ScienceDirect Topics. Docosanol — overview (Agricultural and Biological Sciences).
• Wikipedia. 1-Docosanol.
• U.S. EPA. Supporting Information for Low-Priority Substance 1-Docosanol (CASRN 661-19-8).
• HIV i-Base. Topical docosanol may be beneficial in treating HIV-related Kaposi's sarcoma.